我院2007-2009年抗肿瘤药及其中《中国国家处方集》遴选药物使用情况分析  

Analysis of the Utilization of Antitumor Drugs and National Formulary Medicines of It in Our Hospital during 2007-2009

作　　者：程建娥 张藜莉 李影 申丽萍 

机构地区：[1]煤炭总医院,北京市100028

出　　处：《中国药房》2011年第44期4192-4195,共4页China Pharmacy

摘　　要：目的:了解我院抗肿瘤药及其中《中国国家处方集》遴选药物的使用情况,为进一步合理用药提供参考。方法:对我院2007—2009年抗肿瘤药销售金额、用药频度(DDDs)及日均费用(DDC)等进行统计、分析。结果:各年度抗肿瘤药销售金额占我院药品年销售总额的6.2%～7.2%;国家处方集类抗肿瘤药物占所有抗肿瘤药的73.1%,销售比例为56.8%～63.6%,并呈现递增趋势。其他抗肿瘤药及辅助治疗药和中成药DDC相对较低,DDDs排序在3年中稳居前列。结论:抗肿瘤用药倾向于高效、低毒、价格相对合理的国家处方集类遴选药物,用药方案倾向于多样化的综合治疗原则,用药结构不尽合理,但用药趋势符合国家基本药物制度的用药引导方向。OBJECTIVE： To investigate the utilization of antitumor drugs and the national formulary medicines of it in our hospital. METHODS： A statistical analysis was performed on the consumption sum, DDDs and DDC of antitumor drugs and national essential medicines of them in our hospital from 2007 to 2009. RESULTS： The consumption sum of antitumor drugs accounted for 6.2%～7.2% of the total. 73.1% kinds of antitumor drugs were national formulary. The proportion of essential medicines sales amount had increased from 56.8% to 63.6%. The DDC of adjuvant drugs, other kinds of antitumor drugs and traditional Chinese medicine were low relatively, but DDDs of them took up the front place during 3 years. CONCLUSION： The antitumor drugs are inclined to sound curative effects, low toxicity and reasonable price. Medication regimen tends to multiple comprehensive treatment principle, and the structure of drug use has some unreasonable aspects. The trend of drugs use is in line with the guideline of national drug rational use.

关 键 词：国家处方集 抗肿瘤药 应用分析 

分 类 号：R95[医药卫生—药学]